Lineage Cell Therapeutics (LCTX) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs
May 13, 2021 4:05 PM EDTOpRegen® Clinical Data Continued to Demonstrate Improvements in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) Worldwide License Agreement Secured for a Cancer Immunotherapy Candidate Based on the Lineage VAC Platform Exclusive Agreement Secured to Evaluate a Novel System for Enhanced Delivery of OPC1 Board of Directors Enhanced with Appointments of Healthcare Leaders, Drs. Anula Jayasuriya and Dipti Amin Current Cash and Marketable Securities Expected to Support Operations Well Into 2023
CARLSBAD, Calif.--(BUSINESS... More
